Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Spectrum Pharma Inc (NQ: SPPI )

1.030 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.030
Bid (Size) 1.020 (51)
Ask (Size) 1.040 (5)
Prev. Close 1.030
Today's Range 1.030 - 1.030
52wk Range 0.3150 - 1.360
Shares Outstanding 164,071,943
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Spectrum Pharmaceuticals Stockholders Vote “FOR” Proposed Transaction with Assertio Holdings, Inc.
From Spectrum Pharmaceuticals, Inc.
Via Business Wire
SPECTRUM PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Spectrum Pharmaceuticals, Inc. - SPPI
From Kahn Swick & Foti, LLC
Via Business Wire

Performance

YTD
+169.28%
+169.28%
1 Month
N/A
N/A
3 Month
+8.65%
+8.65%
6 Month
+44.06%
+44.06%
1 Year
+115.62%
+115.62%

More News

Read More
Are (More) Big Gains Ahead for This Small Cap Biotech Stock?
Via MarketBeat
Topics Initial Public Offering
Exposures Securities Market
Expert Ratings for Spectrum Pharma
Via Benzinga
Why Semtech Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Spectrum Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
From Spectrum Pharmaceuticals, Inc.
Via Business Wire
Undervalued Biotech Stocks to Watch After Enzolytics’ (OTC:ENZC) 300% Run: RMED, SPPI, HALB, VXRT
Via AB Newswire
Spectrum Pharma: Q1 Earnings Insights
Via Benzinga
Spectrum Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Update
From Spectrum Pharmaceuticals, Inc.
Via Business Wire
7 A-Rated Stocks to Buy for May 2023
Via InvestorPlace
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE - UNVR)
From Brodsky & Smith LLC
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For April 26, 2023
Via Benzinga
SPECTRUM PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Spectrum Pharmaceuticals, Inc. - SPPI
From Kahn Swick & Foti, LLC
Via Business Wire
Dow Dips Over 300 Points; McDonald's Beats Q1 Expectations
Via Benzinga
Why GE HealthCare Technologies Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE – UNVR)
From Brodsky & Smith LLC
Via GlobeNewswire
Assertio Scoops Up Spectrum Pharma In $248M Stock Deal
Via Benzinga
SPPI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Spectrum Pharmaceuticals, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
What Is Going on With In8bio (INAB) Stock Today?
Via InvestorPlace
Why Is TRACON Pharma (TCON) Stock Down 51% Today?
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Is Vyant Bio (VYNT) Stock Down 35% Today?
Via InvestorPlace
Why Is Spectrum Pharmaceuticals (SPPI) Stock Up 35% Today?
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.